A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 50 microg/g CREAM IN SUBJECTS WITH ACNE VULGARIS

Trial Profile

A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 50 microg/g CREAM IN SUBJECTS WITH ACNE VULGARIS

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs Trifarotene (Primary)
  • Indications Acne vulgaris
  • Focus Adverse reactions; Registrational
  • Sponsors Galderma
  • Most Recent Events

    • 29 Mar 2017 This trial was completed in Hungary (end date: 2017-02-23), according to European Clinical Trials Database.
    • 19 Mar 2017 This trial ha been completed in Czech Republic (End date:2017-02-23) as per European Clinical Trials Database record.
    • 27 Apr 2016 Planned End Date changed from 1 Aug 2017 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top